Sagimet Biosciences Inc
For the period ended Dec 31, 2024. Filed Mar 12, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 12, 2025
SGMT$10.83+9.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets
(in thousands, except for share and per share amounts)
| | | | | | | |
|---|---|---|---|---|---|---|
| · · | ||||||
| · · As of | ||||||
| · · December 31, · · December 31, | ||||||
| | 2024 | 2023 | ||||
| Assets | | | | | | |
| Current assets: · · | ||||||
| Cash and cash equivalents | | $75,840 | | $75,139 | ||
| Short-term marketable securities | | 75,410 | | 19,758 | ||
| Prepaid expenses and other current assets | | | 1,524 | | | 1,749 |
| Total current assets | | | 152,774 | | | 96,646 |
| Long-term marketable securities | | | 7,408 | | | — |
| Operating lease right-of-use assets | | | 77 | | | 73 |
| Total assets | | $160,259 | | $96,719 | ||
| Liabilities and stockholders’ equity | | | ||||
| Current liabilities: | | | ||||
| Accounts payable | | $1,425 | | $186 | ||
| Accrued expenses and other current liabilities (includes nil and $31 payable to related parties as of December 31, 2024 and 2023, respectively) | | 2,951 | | 5,403 | ||
| Operating lease liabilities | | 78 | | 65 | ||
| Total current liabilities | | 4,454 | | 5,654 | ||
| Commitments and contingencies (Note 6) | | | ||||
| Stockholders’ equity: | | | ||||
| Undesignated preferred stock, $0.0001 per share: 10,000,000 shares authorized; no shares issued and outstanding at December 31, 2024 and 2023 | | | — | | | — |
| Series A common stock, $0.0001 per share: 500,000,000 shares authorized; 30,674,855 and 21,375,402 shares issued and outstanding at December 31, 2024 and 2023 | | | 3 | | | 2 |
| Series B common stock, $0.0001 per share: 15,000,000 shares authorized; 1,520,490 shares issued and outstanding at December 31, 2024 and 2023 | | | — | | | — |
| Additional paid-in capital | | 450,883 | | 340,777 | ||
| Accumulated deficit | | (295,311) | | (249,744) | ||
| Accumulated other comprehensive income | | 230 | | 30 | ||
| Total stockholders’ equity | | | 155,805 | | 91,065 | |
| Total liabilities and stockholders’ equity | | $160,259 | | $96,719 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.